The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
(Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverNvidia Sales Grow So Fast That Wall Street Can’t Keep UpJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Russia Is Storing Up a Crime Wave When Its War on Ukraine EndsNasdaq Futures Un
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.